Facebook Twitter LinkedIn Google Plus RSS

Sales at Celgene rise 17 percent in second quarter

By ,

Net product sales at pharmaceutical giant Celgene Corp. climbed to $1.56 billion in the second quarter of 2013, a 17 percent increase over the same period last year, according to the company's most recent earnings report.

In that same time, adjusted net income at the Summit-based company rose 20 percent, to $653 million. Total revenue also was up for the quarter, climbing to $1.59 billion, from $1.36 billion last year.

Celgene specializes in developing drugs to treat cancer and inflammatory diseases.

Reporter Mary Johnson is @mjohns422 on Twitter.

You May Have Missed...

Write to the Editorial Department at editorial@njbiz.com

Related Stories

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy


Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!